Literature DB >> 7049212

Side effects occurring during administration of epoprostenol (prostacyclin, PGI2), in man.

H Pickles, J O'Grady.   

Abstract

1 Fifty infusions of epoprostenol (PGI2) were made, usually increasing the infusion rate until adverse effects were encountered. The volunteers were appraised that they might experience headache and facial flushing. 2 Facial flushing, headache, tachycardia and decrease in diastolic blood pressure were seen in almost all subjects. Erythema over the venous infusing site was also encountered in 13 infusions. Less common effects were sudden bradycardia, pallor and sweating--the vagal reflex--(seven times) and chest pain (twice). Other complaints included restlessness, abdominal discomfort, nausea and drowsiness. 3 The literature on side effects reported during PGI2 infusion is reviewed and recommendations are made concerning administration of PGI2.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7049212      PMCID: PMC1427755          DOI: 10.1111/j.1365-2125.1982.tb01959.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  46 in total

1.  Prostacyclin deficiency in thrombotic thrombocytopenic purpura.

Authors:  C N Hensby; P J Lewis; P Hilgard; G J Mufti; J Hows; J Webster
Journal:  Lancet       Date:  1979-10-06       Impact factor: 79.321

2.  A double blind placebo controlled crossover study of prostacyclin in man.

Authors:  G A FitzGerald; L A Friedman; I Miyamori; J O'Grady; P J Lewis
Journal:  Life Sci       Date:  1979-08-20       Impact factor: 5.037

3.  Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men.

Authors:  A Szczeklik; R J Gryglewski; R Nizankowski; J Musiał; R Pietoń; J Mruk
Journal:  Pharmacol Res Commun       Date:  1978-06

4.  Effect of prostacyclin on perfusion pressure, electrical activity, rate and force of contraction in isolated rat and rabbit hearts.

Authors:  M Karazyn; D F Horrobin; M S Manku; S C Cunnane; R A Karmali; A I Ally; R O Morgan; K C Nicolaou; W E Barnette
Journal:  Life Sci       Date:  1978-06-19       Impact factor: 5.037

5.  Treatment of pregnancy hypertension with prostacyclin.

Authors:  J Fidler; M J Bennett; M de Swiet; C Ellis; P J Lewis
Journal:  Lancet       Date:  1980-07-05       Impact factor: 79.321

6.  Use of prostacyclin in persistent fetal circulation.

Authors:  J E Lock; P M Olley; F Coceani; P R Swyer; R D Rowe
Journal:  Lancet       Date:  1979-06-23       Impact factor: 79.321

7.  Federation of American Societies for Experimental Biology. 64th Annual Meeting. Anaheim, California. April 13--18, 1980. Abstracts of papers. 3014--4925.

Authors: 
Journal:  Fed Proc       Date:  1980-03-01

8.  Successful therapy of advanced arteriosclerosis obliterans with prostacyclin.

Authors:  A Szczeklik; R Nizankowski; S Skawinski; J Szczeklik; P Gluszko; R J Gryglewski
Journal:  Lancet       Date:  1979-05-26       Impact factor: 79.321

9.  Prostacyclin to prevent platelet activation during charcoal haemoperfusion in fulminant hepatic failure.

Authors:  A E Gimson; P G Langley; R D Hughes; J Canalese; P J Mellon; R Williams; H F Woods; M J Weston
Journal:  Lancet       Date:  1980-01-26       Impact factor: 79.321

10.  Effects of intravenous infusion of prostacyclin (PGI2) in man.

Authors:  J O'Grady; S Warrington; M J Moti; S Bunting; R Flower; A S Fowle; E A Higgs; S Moncada
Journal:  Prostaglandins       Date:  1980-02
View more
  20 in total

1.  Eisenmenger's Syndrome.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-12

2.  Hypotension in response to iloprost, a prostacyclin analogue.

Authors:  J W Upward; H A Strong; C F George; B C Ogilive; V Challenor; N Conway
Journal:  Br J Clin Pharmacol       Date:  1986-02       Impact factor: 4.335

3.  Prostaglandin therapy in severe limb ischemia.

Authors:  B J Pardy; H H Eastcott
Journal:  World J Surg       Date:  1983-05       Impact factor: 3.352

4.  The cardiovascular and platelet actions of 9 beta-methyl carbacyclin (ciprostene), a chemically stable analogue of prostacyclin, in the dog and monkey.

Authors:  G Allan; M J Follenfant; P Lidbury; P L Oliver; B J Whittle
Journal:  Br J Pharmacol       Date:  1985-06       Impact factor: 8.739

5.  Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.

Authors:  A H Gershlick; D Spriggins; S W Davies; Y D Syndercombe Court; J Timmins; A D Timmis; M T Rothman; C Layton; R Balcon
Journal:  Br Heart J       Date:  1994-01

6.  Effect of indomethacin on cerebral blood flow, carbon dioxide reactivity and the response to epoprostenol (prostacyclin) infusion in man.

Authors:  H Pickles; M M Brown; M Thomas; A H Hewazy; S Redmond; E Zilkha; J Marshall
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-01       Impact factor: 10.154

7.  The cardiovascular and platelet effects of epoprostenol (prostacyclin, PGI2) are unaffected by beta-adrenoceptor blockade in man.

Authors:  S Hassan; H Pickles; A Fish; C Burke; S Warrington; J O'Grady
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

8.  Effects of a stable prostaglandin analogue, L-644,122, in healthy and hypertensive men.

Authors:  J M Ritter; J R Ludgin; L A Scharschmidt; R D Smith; M J Dunn
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  A chemically stable analogue, 9 beta-methyl carbacyclin, with similar effects to epoprostenol (prostacyclin, PGI2) in man.

Authors:  J O'Grady; A Hedges; B J Whittle; L A Al-Sinawi; Q A Mekki; C Burke; S G Moody; M J Moti; S Hassan
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

10.  Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin).

Authors:  D K Jones; T W Higenbottam; J Wallwork
Journal:  Br Heart J       Date:  1987-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.